Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT06744556
VHAG in Treating R/R T-ALL/LBL
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT06742463
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 72
- Registration Number
- NCT06742086
- Locations
- 🇺🇸
Acpru /Id# 272979, Grayslake, Illinois, United States
Demethylating Agents Combined with Venetoclax for High-risk T-Cell Lymphoma/leukemia Post-Transplant Relapse Prevention
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 59
- Registration Number
- NCT06686108
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 93
- Registration Number
- NCT06672146
Venetoclax + Azacitidine in Patients with Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Target Recruit Count
- 29
- Registration Number
- NCT06668558
- Locations
- 🇪🇸
University Hospital Son Espases, Palma de Mallorca, Baleares, Spain
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain
🇪🇸Institut Catala D oncologia Badalona, Badalona, Cataluña, Spain
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 52
- Registration Number
- NCT06660368
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: IbrutinibDrug: LenalidomideProcedure: Magnetic Resonance ImagingBiological: ObinutuzumabProcedure: Positron Emission TomographyDrug: PrednisoneDrug: Venetoclax
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT06649812
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 83
- Registration Number
- NCT06643962
- Locations
- 🇨🇳
Affiliated hospital of Nantong University, Nantong, Jiangsu, China
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Jennifer R. Brown, MD, PhD
- Target Recruit Count
- 64
- Registration Number
- NCT06644183
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.